Skip to main content

Table 2 Medications at baseline

From: Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study

Sulfonylureas (%) 21
Biguanides (%) 63
Alpha-GIs (%) 10
Glinides (%) 0
TZDs (%) 16
DPP4 inhibitors (%) 63
GLP1 receptor agonists (%) 5
ACEIs (%) 5
ARBs (%) 37
Calcium channel blockers (%) 32
Beta-blockers (%) 5
Alpha-blockers (%) 5
Diuretics (%) 0
Statins (%) 53
Fibrates (%) 5
Anti-platelet agents (%) 32
  1. ACEIs angiotensin converting enzyme inhibitors, ARBs angiotensin receptor blockers, DPP4 dipeptidyl peptidase 4, GIs glycosidase inhibitors, GLP1 glucagon-like peptide 1, TZDs thiazolidinediones